Product Description
to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys). to treat hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated with sorafenib (Nexafar). Used in combination with nivolumab (Opdivo) to treat advanced RCC in patients who have not yet received a treatment for RCC. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells (Sourced from: https://medlineplus.gov/druginfo/meds/a616037.html)
Mechanisms of Action: VEGFR2 Inhibitor,C-Met Inhibitor,AXL Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay
Approved Indications: Thyroid Cancer | Oncology Unspecified
Known Adverse Events: Hypertension | Abdominal Pain | Labor Pain | Pain Unspecified | Stomatitis | Lymphopenia | Thrombocytopenia | Neutropenia | Hypocalcemia | Hypophosphatemia | Constipation | Diarrhea
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: Exelixis
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Adenocarcinoma|Bladder Cancer|Carcinoma, Merkel Cell|Head and Neck Cancer|Hepatocellular Carcinoma|Kidney Cancer|Lung Cancer|Medullary Carcinoma|Melanoma|Non-Small-Cell Lung Cancer|Prostate Cancer|Renal Cell Carcinoma|Thyroid Cancer|Triple Negative Breast Cancer
Phase 2: Abnormalities, Multiple|Adrenocortical Carcinoma|Anal Cancer|Anaplastic Thyroid Carcinoma|Brain Cancer|Carcinoid Tumor|Cervical Cancer|Clear Cell Sarcoma|Colorectal Cancer|Endocrine Gland Cancer|Endometrial Cancer|Esophageal Cancer|Gastrointestinal Cancer|Glioblastoma|Histiocytoma, Malignant Fibrous|Hodgkin Lymphoma|Liver Cancer|Liver Transplant|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Meningioma|Multiple Myeloma|Neuroblastoma|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Oncology Unspecified|Oropharyngeal Cancer|Osteosarcoma|Ovarian Cancer|Pancreatic Cancer|Papillary Carcinoma|Paraganglioma|Pheochromocytoma|Sarcoma|Sarcoma, Ewing|Seminoma|Small Cell Lung Cancer|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Urologic Cancer|Vision, Low
Phase 1: Central Nervous System Cancer|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| F-FR-60000-023 | P2 |
Unknown Status |
Renal Cell Carcinoma |
2099-09-30 |
|
| CARE1 | P3 |
Recruiting |
Renal Cell Carcinoma|Kidney Cancer |
2032-05-05 |
|
| SAMURAI | P2 |
Recruiting |
Renal Cell Carcinoma |
2028-06-15 |
|
| NCT06132945 | P1 |
Recruiting |
Brain Cancer|Renal Cell Carcinoma |
2027-11-01 |